Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Eurofins-Cerep's FCF Margin % or its related term are showing as below:
XPAR:ALECR'
s FCF Margin % Range Over the Past 10 Years
Min: -8.9 Med: 6.57 Max: 13.01
Current: -8.9
During the past 13 years, the highest FCF Margin % of Eurofins-Cerep was 13.01%. The lowest was -8.90%. And the median was 6.57%.
XPAR:ALECR's FCF Margin % is ranked worse than 60.1% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.6
vs XPAR:ALECR: -8.90
Eurofins-Cerep FCF Margin % Related Terms
Eurofins-Cerep FCF Margin % Historical Data
* Premium members only.
The historical data trend for Eurofins-Cerep's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALECR vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Eurofins-Cerep's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins-Cerep FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins-Cerep's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Eurofins-Cerep's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins-Cerep (XPAR:ALECR) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Eurofins-Cerep and its competitors. According to the industry distribution chart, Eurofins-Cerep ranks #122 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 60.1%.
Is Eurofins-Cerep's FCF Margin % too high?
Eurofins-Cerep's current FCF Margin % is 0.00%. Based on the distribution chart, Eurofins-Cerep ranks #122 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins-Cerep has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Eurofins-Cerep's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins-Cerep ranks #122 out of 203 companies for FCF Margin %. This places Eurofins-Cerep in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Eurofins-Cerep and its competitors. Eurofins-Cerep's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins-Cerep stock overvalued right now?
Eurofins-Cerep (XPAR:ALECR) has a current FCF Margin % of 0.00%. The stock's GF Value™ is €20,317.48, compared to a current price of €16,300.00 — trading 19.8% below its estimated fair value. The current FCF Margin % is 0.00%. Eurofins-Cerep's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Eurofins-Cerep (XPAR:ALECR), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins-Cerep (XPAR:ALECR) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins-Cerep stock appears to be undervalued.
The current stock price of €16,300.00 is trading 19.8% below its estimated GF Value™ of €20,317.48.
Key valuation signals for XPAR:ALECR:
FCF Margin %: 0.00%
GF Value™: €20,317.48 vs. price of €16,300.00 (19.8% below fair value)
No single metric tells the full story. See the XPAR:ALECR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.
27GF Score
Get the complete analysis for XPAR:ALECR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALECR has been successfully added to your 
